Viral hepatitis
67 results
1 - 67
Bile acids for viral hepatitis- Glucocorticosteroids for viral hepatitis C
- Interferon for acute hepatitis C
- Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C
- Phyllanthus species for chronic hepatitis B virus infection: Cochrane systematic review
- Vaccines for prophylaxis of viral infections in patients with hematological malignancies: Cochrane systematic review
- Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow‐responder adult patients
- Colchicine for alcoholic and non‐alcoholic liver fibrosis and cirrhosis
- Immunoglobulins for preventing hepatitis A: Cochrane systematic review
- Hepatic late adverse effects after antineoplastic treatment for childhood cancer
- Medicinal herbs for hepatitis C virus infection
- Ribavirin monotherapy for chronic hepatitis C
- Chinese medicinal herbs for asymptomatic carriers of hepatitis B virus infection
- Caesarean section versus vaginal delivery for preventing mother to infant hepatitis C virus transmission
- Entecavir for children and adults with chronic hepatitis B
- Xiao Chai Hu Tang, a herbal medicine, for chronic hepatitis B
- Chinese medicinal herbs for chronic hepatitis B
- Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma: Cochrane systematic review
- Ribavirin plus interferon versus interferon for chronic hepatitis C
- Branched‐chain amino acids for people with hepatic encephalopathy
- Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus
- Bicyclol for chronic hepatitis C
- Bicyclol for chronic hepatitis B
- Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases
- Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infection
- Liver fibrosis stage based on the four factors (FIB‐4) score or Forns index in adults with chronic hepatitis C
- Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis
- Pharmacological interventions for acute hepatitis B infection
- Treatment for hepatitis C virus‐associated mixed cryoglobulinaemia
- Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation
- Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C
- Pharmacological interventions for acute hepatitis C infection
- Interferon for interferon naive patients with chronic hepatitis C: Cochrane systematic review
- Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease
- Hepatitis B immunoglobulin during pregnancy for prevention of mother‐to‐child transmission of hepatitis B virus
- Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease)
- Aminoadamantanes versus other antiviral drugs for chronic hepatitis C
- Interferon alpha for chronic hepatitis D
- Gloves, extra gloves or special types of gloves for preventing percutaneous exposure injuries in healthcare personnel: Cochrane systematic review
- Antioxidant supplements for liver diseases
- Liver and spleen stiffness as assessed by vibration controlled transient elastography for diagnosing clinically significant portal hypertension in comparison with other elastography‐based techniques in adults with chronic liver disease
- Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C
- Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV‐infected, treatment‐naive adults
- Aminoadamantanes for chronic hepatitis C
- Abacavir‐based triple nucleoside regimens for maintenance therapy in patients with HIV
- Expanded polytetrafluoroethylene (ePTFE)‐covered stents versus bare stents for transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
- Improving vaccination uptake among adolescents
- Granulocyte colony‐stimulating factor with or without stem or progenitor cell or growth factors infusion for people with compensated or decompensated advanced chronic liver disease
- N‐acetylcysteine for non‐paracetamol (acetaminophen)‐related acute liver failure
- Psychosocial interventions for stimulant use disorder